TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17159174

Group type: EXPERIMENTAL
Intervention: Indometacin (75 mg) sustained release once daily for six weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo once daily for six weeks
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Indometacin
Number of subjects: 121
Study: 12715306

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 301
Study: 15971244

Group type: EXPERIMENTAL
Intervention: High-calorie milkshake preload
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Food and eating-related thought suppression condition
Number of subjects: 64

Group type: COMPARATOR
Intervention: No suppression control condition
Number of subjects: 64
Study: 10353372

Group type: EXPERIMENTAL
Intervention: Dimensional integration task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective attention task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus integrality and separability manipulations
Number of subjects: 0
Study: 7478405

Group type: EXPERIMENTAL
Intervention: 99Tcm-tetrofosmin with exercise stress
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: 99Tcm-tetrofosmin with dobutamine stress
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: 99Tcm-tetrofosmin overall
Number of subjects: 297
Study: 1785237

Group type: EXPERIMENTAL
Intervention: isoflurane group
Number of subjects: 52

Group type: COMPARATOR
Intervention: control group
Number of subjects: 52
Study: 7054760

Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisuccinate, 50 mg/kg body weight
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 29052033

Group type: EXPERIMENTAL
Intervention: Perturbation-based therapy (random-perturbation exercise, 13 weeks, 2 times per week, 1.5 hours per session)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific training)
Number of subjects: 40
Study: 25304999

Group type: EXPERIMENTAL
Intervention: Thermal Tissue Welder (TW)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Monopolar Electrocautery (EC)
Number of subjects: 48
Study: 23860247

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Late parenteral nutrition
Number of subjects: 15
Study: 21237718

Group type: EXPERIMENTAL
Intervention: Triple antiretroviral prophylaxis (300 mg zidovudine, 150 mg lamivudine, and 400 mg lopinavir plus 100 mg ritonavir twice daily until cessation of breastfeeding, maximum 6.5 months postpartum)
Number of subjects: 882

Group type: COMPARATOR
Intervention: Zidovudine and single-dose nevirapine (300 mg zidovudine twice daily until delivery, 600 mg zidovudine plus 200 mg nevirapine at onset of labour, and after protocol amendment, 300 mg zidovudine twice daily and 150 mg lamivudine twice daily for 1 week postpartum)
Number of subjects: 882
Study: 19373709

Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (once‐ or twice‐weekly for 4‐12 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 55
Study: 17766660

Group type: EXPERIMENTAL
Intervention: Gemcitabine and docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel (single agent)
Number of subjects: 0
Study: 15468406

Group type: EXPERIMENTAL
Intervention: Artecoll
Number of subjects: 251

Group type: COMPARATOR
Intervention: Collagen (control)
Number of subjects: 251
Study: 11432768

Group type: EXPERIMENTAL
Intervention: Micronutrient and single cell oil supplement containing docosahexaenoic acid
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dietary advice and general lifestyle advice
Number of subjects: 55

Group type: COMPARATOR
Intervention: Unsupplemented, inadequate-diet group
Number of subjects: 55
Study: 9543281

Group type: EXPERIMENTAL
Intervention: Rhinovirus 16 (RV16) inoculation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7996818

Group type: EXPERIMENTAL
Intervention: New preservative-free tear substitute (Oculotect fluid sine)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Previous treatment with artificial tears
Number of subjects: 59
Study: 3055456

Group type: EXPERIMENTAL
Intervention: Bed nets (mosquito nets) used correctly by children
Number of subjects: 396

Group type: COMPARATOR
Intervention: No bed nets (control group)
Number of subjects: 396
Study: 30094970

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) - a predominantly organic diet high in fruit, vegetables, whole grains, and fish.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Average Danish Diet (ADD) - a diet higher in imported and processed foods.
Number of subjects: 146

Group type: COMPARATOR
Intervention: NND vs ADD
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: NND
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: NND and ADD
Number of subjects: 146
Study: 28750673

Group type: EXPERIMENTAL
Intervention: EuroFIT program
Number of subjects: 1000
Study: 26650626

Group type: EXPERIMENTAL
Intervention: Faldaprevir and deleobuvir with ribavirin
Number of subjects: 362
Study: 24199898

Group type: EXPERIMENTAL
Intervention: Nurse initiated reinsertion of NGT (NIRNGT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard NGT insertion protocol
Number of subjects: 22
Study: 21359920

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture combined with Fluoxetine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fluoxetine only (Control)
Number of subjects: 75
Study: 21191332

Group type: EXPERIMENTAL
Intervention: Splat Oral Care Foam 2 in 1
Number of subjects: 0
Study: 17701405

Group type: EXPERIMENTAL
Intervention: 40 mg PO omeprazole (young subjects)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 20 mg IV omeprazole (young subjects)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 mg IV omeprazole (elderly subjects)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HI3h after omeprazole IV
Number of subjects: 48
Study: 16393158

Group type: EXPERIMENTAL
Intervention: Pregabalin flexible dose (150 and 300 mg/day for 2 weeks each; 450 and 600 mg/day for 4 weeks each, BID)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Pregabalin fixed dose (600 mg/day BID)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Pregabalin fixed dose vs flexible dose
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Pregabalin flexible dose
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Pregabalin fixed dose
Number of subjects: 341
Study: 12228785

Group type: EXPERIMENTAL
Intervention: Electrophysiology (EP) testing
Number of subjects: 572

Group type: COMPARATOR
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 572
Study: 10215096

Group type: EXPERIMENTAL
Intervention: Subjects observing target locations in the light
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subjects observing target LEDs in the dark
Number of subjects: 24
Study: 8653534

Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg per day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2141262

Group type: EXPERIMENTAL
Intervention: N2O-O2 enflurane
Number of subjects: 185

Group type: COMPARATOR
Intervention: Air-O2 enflurane
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: IV lidocaine (omitted in randomly chosen cases)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Fentanyl (postoperatively for pain)
Number of subjects: 185
Study: 220536

Group type: EXPERIMENTAL
Intervention: Interferon (administered for six weeks starting on the day of transplantation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon and antithymocyte globulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon and placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Number of subjects: 0
Study: 30897038

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 358
Study: 27702806

Group type: EXPERIMENTAL
Intervention: 1.25% fluoride gel application
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo gel application
Number of subjects: 46
Study: 26496331

Group type: EXPERIMENTAL
Intervention: Flutter device (oscillating positive expiratory pressure)
Number of subjects: 15
Study: 23621629

Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS) with delayed withdrawal (intra-operative methylprednisolone weaned by six months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: CS-free regimen with basiliximab, tacrolimus, and enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both CS and CS-free groups
Number of subjects: 39
Study: 21536191

Group type: EXPERIMENTAL
Intervention: Heavy rotational force (225 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Light rotational force (25 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Heavy rotational forces
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Compression areas (buccal‐distal and lingual‐mesial surfaces)
Number of subjects: 15
Study: 19702208

Group type: EXPERIMENTAL
Intervention: 1 microg x kg(‐1) IV fentanyl
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 3 microg x kg(‐1) IV fentanyl
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 5 microg x kg(‐1) IV fentanyl
Number of subjects: 318
Study: 16720765

Group type: EXPERIMENTAL
Intervention: Total knee replacement with cemented polyethylene patellar component
Number of subjects: 100

Group type: COMPARATOR
Intervention: Total knee replacement without cemented polyethylene patellar component
Number of subjects: 100
Study: 15663094

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (CDDP+FU, TAX+FU, CDDP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Surgical treatment only (Control group)
Number of subjects: 70
Study: 11468047

Group type: EXPERIMENTAL
Intervention: Behavioural programme
Number of subjects: 610

Group type: COMPARATOR
Intervention: Educational intervention
Number of subjects: 610

Group type: COMPARATOR
Intervention: Control
Number of subjects: 610
Study: 9639767

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 micrograms intra‐vaginally every 3 hours until active labor)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ricinus oil meal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 60
Study: 8480881

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Mini-cholecystectomy
Number of subjects: 363
Study: 3111702

Group type: EXPERIMENTAL
Intervention: Combination of 3 mg dihydroergocristine and 100 mg levo‐5‐hydroxytryptophan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30308200

Group type: EXPERIMENTAL
Intervention: Donor cornea with preservation time (PT) of 0-7 days
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Donor cornea with preservation time (PT) of 8-14 days
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Grafts that experienced rejection (n=27)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Grafts that did not experience rejection (n=886)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Definite graft rejection (n=12 of 44 eyes)
Number of subjects: 1090
Study: 27498100

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bilastine 50 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24852180

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 36
Study: 23071204

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus reuteri, 5 drops containing 10^8 CFU)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 750
Study: 20600033

Group type: EXPERIMENTAL
Intervention: Endoscopic tri-modal imaging (ETMI)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard video endoscopy (SVE)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Endoscopic tri-modal imaging (ETMI) with detailed inspection using narrow band imaging (NBI)
Number of subjects: 87
Study: 17850684

Group type: EXPERIMENTAL
Intervention: remifentanil 0.75 microg kg(‐1) (Group 2)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg kg(‐1) (Group 3)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: remifentanil 1.25 microg kg(‐1) (Group 4)
Number of subjects: 124

Group type: COMPARATOR
Intervention: normal saline (Group 1)
Number of subjects: 124
Study: 15220247

Group type: EXPERIMENTAL
Intervention: Fixed-dose trandolapril-verapamil (FDTV) 2 mg trandolapril/180 mg verapamil once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trandolapril 2 mg once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trandolapril
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fixed-dose trandolapril-verapamil (FDTV)
Number of subjects: 60
Study: 11576097

Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.1 microg x kg(‐1) x min(‐1) (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 9850900

Group type: EXPERIMENTAL
Intervention: 50 units of the immunotoxin MDX‐RA
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 175 units of the immunotoxin MDX‐RA
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 8010427

Group type: EXPERIMENTAL
Intervention: Active aspiration (AA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonactive aspiration (NAA)
Number of subjects: 40
Study: 2802896

Group type: EXPERIMENTAL
Intervention: Aspartame (75 mg/kg per day, capsule form, three times daily for 24 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (capsule form, three times daily for 24 weeks)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 869054

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31515355

Group type: EXPERIMENTAL
Intervention: MPT-T (melphalan-prednisolone + thalidomide)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: MPR-R (melphalan-prednisolone + lenalidomide)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: MPT-T
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: MPR-R
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Both MPT-T and MPR-R
Number of subjects: 596
Study: 31546498

Group type: EXPERIMENTAL
Intervention: Group I: Low parameters (AFR = 20 cc/min, BH = 90 cm, vacuum = 400 mmHg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group II: High parameters (AFR = 40 cc/min, BH = 110 cm, vacuum = 650 mmHg)
Number of subjects: 20
Study: 28599034

Group type: EXPERIMENTAL
Intervention: Procellera® applied topically two to three times per week for 2 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatment, moleskin and Tegaderm®
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Procellera®
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Procellera® and SOC
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatment
Number of subjects: 80
Study: 25935299

Group type: EXPERIMENTAL
Intervention: €12.50 monetary incentive
Number of subjects: 0

Group type: COMPARATOR
Intervention: €7.50 monetary incentive
Number of subjects: 0

Group type: COMPARATOR
Intervention: €10.00 monetary incentive
Number of subjects: 0
Study: 22678407

Group type: EXPERIMENTAL
Intervention: Acupressure wristband
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 21724041

Group type: EXPERIMENTAL
Intervention: Humorous video
Number of subjects: 46

Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sense of humor
Number of subjects: 46
Study: 19657846

Group type: EXPERIMENTAL
Intervention: Slow freezing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrification
Number of subjects: 0
Study: 16490895

Group type: EXPERIMENTAL
Intervention: Gum chewing (sugarless gum 3 times daily for 1 hour each until discharge)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 34
Study: 15360122

Group type: EXPERIMENTAL
Intervention: Feigned depression condition
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 22
Study: 11323373

Group type: EXPERIMENTAL
Intervention: Tidal volume breathing (TVB) for 3-5 min at 5, 7, and 10 L/min fresh gas flow (FGF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Four deep breaths (DB) in 0.5 min at 5, 7, and 10 L/min FGF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Eight deep breaths (DB) in 1 min at 7 and 10 L/min FGF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deep breathing extended to 1.5 and 2 min with 10 L/min FGF
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of TVB and DB techniques
Number of subjects: 24

Group type: COMPARATOR
Intervention: Increasing FGF from 5 to 10 L/min
Number of subjects: 24
Study: 9209004

Group type: EXPERIMENTAL
Intervention: Epoetin beta (5 x 500 U/kg bodyweight intravenously over 14 days preoperatively)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (intravenously over 14 days preoperatively)
Number of subjects: 72
Study: 7962395

Group type: EXPERIMENTAL
Intervention: Vitamin A (VITA) at 1 microM for 16 hours
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Tigasone (etretinate, TIG) at 1 microM for 16 hours
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Roaccutane (isotretinoin, ROA) at 1 microM for 16 hours
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vitamin A (VITA), Tigasone (TIG), Roaccutane (ROA) at 1 microM for 16 hours
Number of subjects: 3
Study: 3578544

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31633161

Group type: EXPERIMENTAL
Intervention: Azithromycin mass drug administration (MDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated azithromycin MDA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard microbiological techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted short-term and long-term surveillance
Number of subjects: 0
Study: 29393208

Group type: EXPERIMENTAL
Intervention: Oral methadone dose adjustments to reach plasma R-methadone levels (80-250 ng/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma R-methadone levels in the target range at the beginning of the study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintaining plasma R-methadone target levels (per protocol analysis)
Number of subjects: 0
Study: 27514345

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24916132

Group type: EXPERIMENTAL
Intervention: Food with gadget (Toy)
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Food alone (No Toy)
Number of subjects: 1680
Study: 23702779

Group type: EXPERIMENTAL
Intervention: Topical natamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 0
Study: 20795751

Group type: EXPERIMENTAL
Intervention: Menveo vaccine
Number of subjects: 0
Study: 19052709

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no therapeutic hypothermia)
Number of subjects: 0
Study: 16881934

Group type: EXPERIMENTAL
Intervention: Prolonged thromboprophylaxis with dalteparin (5000 IU once daily for 28 days)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Short-term thromboprophylaxis (dalteparin for 7 days)
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Prolonged thromboprophylaxis with dalteparin
Number of subjects: 590
Study: 12832673

Group type: EXPERIMENTAL
Intervention: gemifloxacin 320 mg once daily for 5 days
Number of subjects: 438

Group type: COMPARATOR
Intervention: clarithromycin 500 mg twice daily for 7 days
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: no further exacerbations
Number of subjects: 438
Study: 11219600

Group type: EXPERIMENTAL
Intervention: Wall Motion (WM) assessment using gated SPECT
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Wall Thickening (WT) assessment using gated SPECT
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Wall Motion (WM) assessment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Wall Thickening (WT) assessment
Number of subjects: 44
Study: 9072891

Group type: EXPERIMENTAL
Intervention: Application of antioxidants in combined treatment of schizophrenic patients
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 185
Study: 1386823

Group type: EXPERIMENTAL
Intervention: ONO‐3708 (3 micrograms.kg‐1.min‐1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3921278

Group type: EXPERIMENTAL
Intervention: Diltiazem (up to 360 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol plus maximum tolerated dose of diltiazem
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and propranolol
Number of subjects: 24
Study: 31402081

Group type: EXPERIMENTAL
Intervention: Experimental exercise (phonation into a resonance flexible tube in water)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control exercise (tongue trill exercise)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo exercise (unvoiced fricative exercise)
Number of subjects: 30
Study: 26726854

Group type: EXPERIMENTAL
Intervention: Brief positive psychotherapy plus usual treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual treatment only
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Brief positive psychotherapy
Number of subjects: 27